EGFR and cancer: Although the two factors that we applied to genes encoding protein kinases and pro-inflammatory cytokines do not specify how these two factors alone can selectively affect germline, somatic, and/or de novo mutations, our analysis on the approved EGFR inhibitor drugs suggests that the threshold for F(i) or proximity to telomeres should be corrected from 50 to 77 Mb [23, 28]—at least for somatic mutations in cancer—to embrace marginal proximity conditions to meet the condition of sufficiently proximal distance to telomeres.